Metrion Biosciences raises £14m from o2h Ventures to expand screening capabilities
The funding round was led by o2h Ventures Therapeutics Fund and supported by existing backers.
Metrion Biosciences is a specialist ion channel contract research organisation and drug discovery business. The firm provides customers with access to a range of high quality assays and screening services.
Metrion Biosciences has closed a fully subscribed funding round to broaden its ion channel screening capabilities and advance research into auto-immune treatments. The capital injection was led by the newly established o2h Ventures Therapeutics Fund, with participation from existing shareholders. The business will use the proceeds to scale its screening operations and study novel inhibitors.
From the founder
"We are pleased to welcome both o2h Ventures Therapeutics Fund as a new shareholder and Sunil Shah, Managing Partner of o2h Ventures Ltd as an observer on the Metrion board."
Keith McCullagh
Chairman at Metrion Biosciences
Investor perspective
"We recognise the ion channel biology space as a potentially very valuable source of new drug targets, which is generating a great interest with pharma companies. The Metrion team has deep expertise, and the Company is emerging as a global leader in ion channel drug discovery."
Sunil Shah
CEO, o2h Ventures
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Metrion Biosciences
Metrion Biosciences provides specialist ion channel screening and drug discovery services.